SGRY — Surgery Partners, Inc.

Surgery Partners, Inc. (SGRY) Q4 and Full Year 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year Net Revenue: $3.3 billion, up 6.2% year-over-year, at the low end of expectations.
• Same-Facility Revenue Growth: 4.9%.
• Adjusted EBITDA: $526 million, a 3.5% increase year-over-year but significantly below expectations.
• Adjusted EBITDA Margin: 15.9%, reflecting a 40 basis points compression.

2. Strategic Updates and Business Highlights

• Surgical Cases: Performed nearly 670,000 surgical cases in 2025, a slight increase from 656,000 in 2024.
• Orthopedic Procedures: Strong growth in orthopedic cases, particularly total joint replacements, with a 15% increase in Q4.
• Physician Recruitment: Nearly 700 physicians recruited in 2025, although transitions contributed to payer mix pressures.
• Capital Deployment: $182 million deployed towards acquisitions, slightly below the target of $200 million.
• De Novo Facilities: Opened four new facilities in Q4, totaling eight for the year, focusing on high-acuity specialties.
• Portfolio Optimization: Ongoing efforts to divest non-core facilities, with a recent joint venture with Baylor Scott & White aimed at improving strategic alignment.

3. Forward Guidance and Outlook

• 2026 Preliminary Guidance: Net revenue expected between $3.3 billion and $3.45 billion, indicating single-digit growth.
• Adjusted EBITDA Guidance: At least $530 million, reflecting a growth of at least 0.7%.
• Long-term Growth Strategy: Confidence in organic growth opportunities remains, with plans to address identified headwinds.

4. Bad News, Challenges, or Points of Concern

• Second Half Performance: Notable headwinds in Q4 due to slower case growth and unfavorable payer mix shifts, particularly in three surgical hospital markets.
• Margin Compression: Fourth quarter margins were pressured by slower case growth and a shift in payer mix, exacerbated by high labor and anesthesia costs.
• Physician Transition Issues: Departures of experienced physicians led to a higher proportion of Medicare patients, impacting revenue mix negatively.
• Execution Challenges: Acknowledgment of the need for improved execution and operational adjustments to address recent performance issues.

5. Notable Q&A Insights

• Leadership Changes: New COO Justin Oppenheimer is focused on improving performance in underperforming facilities.
• Market Dynamics: Management expressed confidence in addressing the identifiable issues affecting performance, with a focus on long-term structural growth.
• Future Updates: Plans for a comprehensive update on portfolio composition and optimization efforts at an upcoming Investor Day, aligned with key milestones.

Overall, while Surgery Partners reported growth in revenue and surgical cases, the company faced significant challenges in the second half of 2025 that impacted margins and performance. The management remains optimistic about long-term growth and is actively working on strategies to address current headwinds.